Using a virion assembly-defective dengue virus as a vaccine approach

Chao Shan, Xuping Xie, Jing Zou, Roland Züst, Bo Zhang, Rebecca Ambrose, Jason Mackenzie, Katja Fink, Pei-Yong Shi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Dengue virus (DENV) is the most prevalent mosquito-transmitted viral pathogen in humans. The recently licensed dengue vaccine has major weaknesses. Therefore, there is an urgent need to develop improved dengue vaccines. Here, we report a virion assembly-defective DENV as a vaccine platform. DENV containing an amino acid deletion (K188) in nonstructural protein 2A (NS2A) is fully competent in viral RNA replication but is completely defective in virion assembly. When transcomplemented with wild-type NS2A protein, the virion assembly defect could be rescued, generating pseudoinfectious virus (PIVNS2A) that could initiate single-round infection. The trans-complementation efficiency could be significantly improved through selection for adaptive mutations, leading to high-yield PIVNS2A production, with titers of >107 infectious-focus units (IFU)/ml. Mice immunized with a single dose of PIVNS2A elicited strong T cell immune responses and neutralization antibodies and were protected from wild-type-virus challenge. Collectively, the results proved the concept of using assembly-defective virus as a vaccine approach. The study also solved the technical bottleneck in producing high yields of PIVNS2A vaccine. The technology could be applicable to vaccine development for other viral pathogens. IMPORTANCE Many flaviviruses are significant human pathogens that pose global threats to public health. Although licensed vaccines are available for yellow fever, Japanese encephalitis, tick-borne encephalitis, and dengue viruses, new approaches are needed to develop improved vaccines. Using dengue virus as a model, we developed a vaccine platform using a virion assembly-defective virus. We show that such an assembly-defective virus could be rescued to higher titers and infect cells for a single round. Mice immunized with the assembly-defective virus were protected from wild-type-virus infection. This vaccine approach could be applicable to other viral pathogens.

Original languageEnglish (US)
Article numbere01002
JournalJournal of Virology
Volume92
Issue number21
DOIs
StatePublished - Nov 1 2018

Fingerprint

Defective Viruses
Dengue virus
Dengue Virus
virion
Virion
Vaccines
vaccines
Dengue Vaccines
dengue
pathogens
Yellow Fever Vaccine
viruses
Japanese Encephalitis
Tick-Borne Encephalitis Viruses
Viruses
Flavivirus
Proteins
Yellow fever virus
amino acid deletion
Tick-borne encephalitis virus

Keywords

  • Dengue virus
  • Flavivirus vaccine
  • NS2A
  • Trans-complementation
  • Viral assembly

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Shan, C., Xie, X., Zou, J., Züst, R., Zhang, B., Ambrose, R., ... Shi, P-Y. (2018). Using a virion assembly-defective dengue virus as a vaccine approach. Journal of Virology, 92(21), [e01002]. https://doi.org/10.1128/JVI.01002-18

Using a virion assembly-defective dengue virus as a vaccine approach. / Shan, Chao; Xie, Xuping; Zou, Jing; Züst, Roland; Zhang, Bo; Ambrose, Rebecca; Mackenzie, Jason; Fink, Katja; Shi, Pei-Yong.

In: Journal of Virology, Vol. 92, No. 21, e01002, 01.11.2018.

Research output: Contribution to journalArticle

Shan, C, Xie, X, Zou, J, Züst, R, Zhang, B, Ambrose, R, Mackenzie, J, Fink, K & Shi, P-Y 2018, 'Using a virion assembly-defective dengue virus as a vaccine approach', Journal of Virology, vol. 92, no. 21, e01002. https://doi.org/10.1128/JVI.01002-18
Shan C, Xie X, Zou J, Züst R, Zhang B, Ambrose R et al. Using a virion assembly-defective dengue virus as a vaccine approach. Journal of Virology. 2018 Nov 1;92(21). e01002. https://doi.org/10.1128/JVI.01002-18
Shan, Chao ; Xie, Xuping ; Zou, Jing ; Züst, Roland ; Zhang, Bo ; Ambrose, Rebecca ; Mackenzie, Jason ; Fink, Katja ; Shi, Pei-Yong. / Using a virion assembly-defective dengue virus as a vaccine approach. In: Journal of Virology. 2018 ; Vol. 92, No. 21.
@article{b3789cc3926e444f84814d1dd545b3b2,
title = "Using a virion assembly-defective dengue virus as a vaccine approach",
abstract = "Dengue virus (DENV) is the most prevalent mosquito-transmitted viral pathogen in humans. The recently licensed dengue vaccine has major weaknesses. Therefore, there is an urgent need to develop improved dengue vaccines. Here, we report a virion assembly-defective DENV as a vaccine platform. DENV containing an amino acid deletion (K188) in nonstructural protein 2A (NS2A) is fully competent in viral RNA replication but is completely defective in virion assembly. When transcomplemented with wild-type NS2A protein, the virion assembly defect could be rescued, generating pseudoinfectious virus (PIVNS2A) that could initiate single-round infection. The trans-complementation efficiency could be significantly improved through selection for adaptive mutations, leading to high-yield PIVNS2A production, with titers of >107 infectious-focus units (IFU)/ml. Mice immunized with a single dose of PIVNS2A elicited strong T cell immune responses and neutralization antibodies and were protected from wild-type-virus challenge. Collectively, the results proved the concept of using assembly-defective virus as a vaccine approach. The study also solved the technical bottleneck in producing high yields of PIVNS2A vaccine. The technology could be applicable to vaccine development for other viral pathogens. IMPORTANCE Many flaviviruses are significant human pathogens that pose global threats to public health. Although licensed vaccines are available for yellow fever, Japanese encephalitis, tick-borne encephalitis, and dengue viruses, new approaches are needed to develop improved vaccines. Using dengue virus as a model, we developed a vaccine platform using a virion assembly-defective virus. We show that such an assembly-defective virus could be rescued to higher titers and infect cells for a single round. Mice immunized with the assembly-defective virus were protected from wild-type-virus infection. This vaccine approach could be applicable to other viral pathogens.",
keywords = "Dengue virus, Flavivirus vaccine, NS2A, Trans-complementation, Viral assembly",
author = "Chao Shan and Xuping Xie and Jing Zou and Roland Z{\"u}st and Bo Zhang and Rebecca Ambrose and Jason Mackenzie and Katja Fink and Pei-Yong Shi",
year = "2018",
month = "11",
day = "1",
doi = "10.1128/JVI.01002-18",
language = "English (US)",
volume = "92",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "21",

}

TY - JOUR

T1 - Using a virion assembly-defective dengue virus as a vaccine approach

AU - Shan, Chao

AU - Xie, Xuping

AU - Zou, Jing

AU - Züst, Roland

AU - Zhang, Bo

AU - Ambrose, Rebecca

AU - Mackenzie, Jason

AU - Fink, Katja

AU - Shi, Pei-Yong

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Dengue virus (DENV) is the most prevalent mosquito-transmitted viral pathogen in humans. The recently licensed dengue vaccine has major weaknesses. Therefore, there is an urgent need to develop improved dengue vaccines. Here, we report a virion assembly-defective DENV as a vaccine platform. DENV containing an amino acid deletion (K188) in nonstructural protein 2A (NS2A) is fully competent in viral RNA replication but is completely defective in virion assembly. When transcomplemented with wild-type NS2A protein, the virion assembly defect could be rescued, generating pseudoinfectious virus (PIVNS2A) that could initiate single-round infection. The trans-complementation efficiency could be significantly improved through selection for adaptive mutations, leading to high-yield PIVNS2A production, with titers of >107 infectious-focus units (IFU)/ml. Mice immunized with a single dose of PIVNS2A elicited strong T cell immune responses and neutralization antibodies and were protected from wild-type-virus challenge. Collectively, the results proved the concept of using assembly-defective virus as a vaccine approach. The study also solved the technical bottleneck in producing high yields of PIVNS2A vaccine. The technology could be applicable to vaccine development for other viral pathogens. IMPORTANCE Many flaviviruses are significant human pathogens that pose global threats to public health. Although licensed vaccines are available for yellow fever, Japanese encephalitis, tick-borne encephalitis, and dengue viruses, new approaches are needed to develop improved vaccines. Using dengue virus as a model, we developed a vaccine platform using a virion assembly-defective virus. We show that such an assembly-defective virus could be rescued to higher titers and infect cells for a single round. Mice immunized with the assembly-defective virus were protected from wild-type-virus infection. This vaccine approach could be applicable to other viral pathogens.

AB - Dengue virus (DENV) is the most prevalent mosquito-transmitted viral pathogen in humans. The recently licensed dengue vaccine has major weaknesses. Therefore, there is an urgent need to develop improved dengue vaccines. Here, we report a virion assembly-defective DENV as a vaccine platform. DENV containing an amino acid deletion (K188) in nonstructural protein 2A (NS2A) is fully competent in viral RNA replication but is completely defective in virion assembly. When transcomplemented with wild-type NS2A protein, the virion assembly defect could be rescued, generating pseudoinfectious virus (PIVNS2A) that could initiate single-round infection. The trans-complementation efficiency could be significantly improved through selection for adaptive mutations, leading to high-yield PIVNS2A production, with titers of >107 infectious-focus units (IFU)/ml. Mice immunized with a single dose of PIVNS2A elicited strong T cell immune responses and neutralization antibodies and were protected from wild-type-virus challenge. Collectively, the results proved the concept of using assembly-defective virus as a vaccine approach. The study also solved the technical bottleneck in producing high yields of PIVNS2A vaccine. The technology could be applicable to vaccine development for other viral pathogens. IMPORTANCE Many flaviviruses are significant human pathogens that pose global threats to public health. Although licensed vaccines are available for yellow fever, Japanese encephalitis, tick-borne encephalitis, and dengue viruses, new approaches are needed to develop improved vaccines. Using dengue virus as a model, we developed a vaccine platform using a virion assembly-defective virus. We show that such an assembly-defective virus could be rescued to higher titers and infect cells for a single round. Mice immunized with the assembly-defective virus were protected from wild-type-virus infection. This vaccine approach could be applicable to other viral pathogens.

KW - Dengue virus

KW - Flavivirus vaccine

KW - NS2A

KW - Trans-complementation

KW - Viral assembly

UR - http://www.scopus.com/inward/record.url?scp=85054020874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054020874&partnerID=8YFLogxK

U2 - 10.1128/JVI.01002-18

DO - 10.1128/JVI.01002-18

M3 - Article

VL - 92

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 21

M1 - e01002

ER -